well done, finally somebody on this forum who actually gets what is meant by the futility analysis.
——It’s all down to determining the probability of being able to achieve the final outcome (endpoint) in total study sample based on what you see at the interim in first roughly quarter of patients in March, as you rightly say.
——All this stuff about clinically and statistically significant is a distraction being pumped by a certain poster.
Ann: Application for quotation of securities - DXB, page-91
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |